Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
US$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest Results [Yahoo! Finance]
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $4.00 price target on the stock.
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates [Yahoo! Finance]